Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMANASDAQ:FUSNNASDAQ:KRYSNASDAQ:RVMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$23.52+1.1%$19.44$6.65▼$25.67$5.59B0.573.69 million shs2.11 million shsFUSNFusion Pharmaceuticals$21.55$21.50$2.31▼$21.60$1.83B-0.691.69 million shsN/AKRYSKrystal Biotech$166.16+0.3%$174.92$141.72▼$219.34$4.80B0.75295,181 shs228,173 shsRVMDRevolution Medicines$40.72+0.2%$37.34$29.17▼$62.40$7.57B1.371.45 million shs1.73 million shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics-2.23%+4.21%+19.82%+44.09%+248.88%FUSNFusion Pharmaceuticals0.00%0.00%0.00%0.00%+0.61%KRYSKrystal Biotech-2.47%-2.03%-5.09%+3.72%+3.77%RVMDRevolution Medicines+0.64%+5.34%+20.88%-5.38%+4.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMAADMA Biologics1.4548 of 5 stars1.61.00.00.03.41.71.9FUSNFusion PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AKRYSKrystal Biotech4.9167 of 5 stars4.53.00.04.72.93.31.9RVMDRevolution Medicines3.769 of 5 stars3.50.00.04.73.42.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 3.25Buy$22.50-4.34% DownsideFUSNFusion Pharmaceuticals 0.00N/AN/AN/AKRYSKrystal Biotech 3.00Buy$222.7134.04% UpsideRVMDRevolution Medicines 3.00Buy$66.6763.72% UpsideCurrent Analyst Ratings BreakdownLatest FUSN, ADMA, RVMD, and KRYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/28/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$221.00 ➝ $240.004/28/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$67.00 ➝ $67.004/8/2025RVMDRevolution MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$59.00 ➝ $59.004/1/2025RVMDRevolution MedicinesStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$78.00 ➝ $64.003/5/2025KRYSKrystal BiotechJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$245.003/4/2025ADMAADMA BiologicsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.003/3/2025RVMDRevolution MedicinesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$72.00 ➝ $73.002/28/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$221.00 ➝ $221.002/27/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$67.002/27/2025RVMDRevolution MedicinesStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$80.00 ➝ $78.002/27/2025RVMDRevolution MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$60.00 ➝ $59.00(Data available from 5/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$426.45M13.11$0.08 per share311.70$0.60 per share39.20FUSNFusion Pharmaceuticals$2.07M885.53N/AN/A$3.07 per share7.02KRYSKrystal Biotech$290.52M16.53$4.22 per share39.38$32.85 per share5.06RVMDRevolution Medicines$742K10,202.66N/AN/A$11.09 per share3.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics-$28.24M$0.8284.0034.09N/A17.80%53.20%26.07%5/7/2025 (Estimated)FUSNFusion Pharmaceuticals-$94.90M-$1.42N/AN/AN/A-4,136.55%-48.74%-36.87%N/AKRYSKrystal Biotech$10.93M$2.9955.5716.48N/A30.69%11.41%10.40%5/6/2025 (Estimated)RVMDRevolution Medicines-$436.37M-$3.57N/AN/AN/AN/A-33.67%-30.08%5/7/2025 (Estimated)Latest FUSN, ADMA, RVMD, and KRYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025ADMAADMA Biologics$0.16N/AN/AN/A$116.40 millionN/A5/7/2025Q1 2025RVMDRevolution Medicines-$1.10N/AN/AN/AN/AN/A5/6/2025Q1 2025KRYSKrystal Biotech$1.35N/AN/AN/A$98.66 millionN/A2/26/2025Q4 2024RVMDRevolution Medicines-$1.01-$1.12-$0.11-$1.12$0.35 millionN/A2/24/2025Q4 2024KRYSKrystal Biotech$1.29$1.52+$0.23$1.52$91.35 million$91.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AFUSNFusion PharmaceuticalsN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.487.093.26FUSNFusion Pharmaceuticals0.2110.6410.64KRYSKrystal BiotechN/A7.287.76RVMDRevolution MedicinesN/A14.2414.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%FUSNFusion Pharmaceuticals72.85%KRYSKrystal Biotech86.29%RVMDRevolution Medicines94.34%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.70%FUSNFusion Pharmaceuticals7.75%KRYSKrystal Biotech13.70%RVMDRevolution Medicines8.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530237.62 million227.64 millionOptionableFUSNFusion Pharmaceuticals10185.06 million78.47 millionOptionableKRYSKrystal Biotech21028.90 million24.71 millionOptionableRVMDRevolution Medicines250185.91 million154.76 millionOptionableFUSN, ADMA, RVMD, and KRYS HeadlinesRecent News About These CompaniesRevolution Medicines (RVMD) Expected to Announce Quarterly Earnings on WednesdayMay 2 at 1:36 AM | americanbankingnews.comRevolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025April 30 at 4:15 PM | globenewswire.comRevolution Medicines (NASDAQ:RVMD) Shares Up 5.8% - Should You Buy?April 30 at 1:33 PM | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Given "Outperform" Rating at WedbushApril 30 at 10:33 AM | marketbeat.comHsbc Holdings PLC Trims Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)April 30 at 5:09 AM | marketbeat.comWedbush Reiterates Outperform Rating for Revolution Medicines (NASDAQ:RVMD)April 30 at 3:33 AM | americanbankingnews.comArtia Global Partners LP Raises Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)April 29 at 7:00 AM | marketbeat.comWhy Revolution Medicines, Inc.’s (RVMD) Stock Is Up 5.47%April 29 at 6:39 AM | aaii.comAquatic Capital Management LLC Buys 78,605 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)April 29 at 6:35 AM | marketbeat.comSusquehanna Fundamental Investments LLC Invests $10 Million in Revolution Medicines, Inc. (NASDAQ:RVMD)April 29 at 6:24 AM | marketbeat.comTower Research Capital LLC TRC Has $808,000 Position in Revolution Medicines, Inc. (NASDAQ:RVMD)April 29 at 4:46 AM | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) is Decheng Capital LLC's 8th Largest PositionApril 28, 2025 | marketbeat.comOxford Asset Management LLP Acquires New Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)April 28, 2025 | marketbeat.comGhisallo Capital Management LLC Makes New $11.25 Million Investment in Revolution Medicines, Inc. (NASDAQ:RVMD)April 28, 2025 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Shares Purchased by Adage Capital Partners GP L.L.C.April 28, 2025 | marketbeat.com7,306 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Acquired by Syon Capital LLCApril 28, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Purchases 552,657 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)April 28, 2025 | marketbeat.comNatixis Sells 83,624 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)April 28, 2025 | marketbeat.comInvesco Ltd. Has $5.15 Million Position in Revolution Medicines, Inc. (NASDAQ:RVMD)April 28, 2025 | marketbeat.comRevolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual MeetingApril 27, 2025 | globenewswire.comLord Abbett & CO. LLC Has $86.55 Million Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)April 27, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying season5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeatIntel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off?By Jeffrey Neal Johnson | April 4, 2025View Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off?FUSN, ADMA, RVMD, and KRYS Company DescriptionsADMA Biologics NASDAQ:ADMA$23.52 +0.25 (+1.07%) Closing price 04:00 PM EasternExtended Trading$23.65 +0.13 (+0.55%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Fusion Pharmaceuticals NASDAQ:FUSNFusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in Hamilton, Canada.Krystal Biotech NASDAQ:KRYS$166.16 +0.47 (+0.28%) Closing price 04:00 PM EasternExtended Trading$172.52 +6.36 (+3.83%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Revolution Medicines NASDAQ:RVMD$40.72 +0.08 (+0.20%) Closing price 04:00 PM EasternExtended Trading$41.32 +0.60 (+1.47%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be Cautious Meta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2 Is It Time to Load Up on Bond ETFs? Palantir Earnings: 1 Bullish Signal and 1 Area of Concern Roblox Stock Gains Momentum and Can Top $100 in 2025 Microsoft Crushes Earnings, What’s Next for MSFT Stock? 3 Biotech Giants Gaining From U.S. Sales and Policy Shifts McDonald’s Insiders Sell Shares! Investors Should Do the Opposite Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
